Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype
- 8 November 2013
- journal article
- clinical trial
- Published by Elsevier BV in Metabolism
- Vol. 63 (3), 365-371
- https://doi.org/10.1016/j.metabol.2013.10.014
Abstract
No abstract availableKeywords
Funding Information
- MERCK IISP 2010
- Eudra CT 2010 (022258-17)
- Spanish Ministry of Health FIS (PI10/00387, PI12/01087)
- RETIC RIC (RD12/0042/0055)
This publication has 31 references indexed in Scilit:
- HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatmentEuropean Heart Journal, 2013
- Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic miceJournal of Lipid Research, 2012
- Lipoprotein(a)Current Opinion in Lipidology, 2012
- Lipoprotein(a) as a cardiovascular risk factor: current statusEuropean Heart Journal, 2010
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJAMA, 2009
- Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCRJournal of Lipid Research, 2009
- Niacin and Lipoprotein(a): Facts, Uncertainties, and Clinical ConsiderationsThe American Journal of Cardiology, 2008
- Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With DyslipidemiaThe American Journal of Cardiology, 2008
- High-Level Expression of Various Apolipoprotein (a) Isoforms by "Transferrinfection": The Role of Kringle IV Sequences in the Extracellular Association with Low-Density LipoproteinBiochemistry, 1994
- cDNA sequence of human apolipoprotein(a) is homologous to plasminogenNature, 1987